219 related articles for article (PubMed ID: 31752122)
21. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
[TBL] [Abstract][Full Text] [Related]
23. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
24. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Di Salvatore M; Pietrantonio F; Orlandi A; Del Re M; Berenato R; Rossi E; Caporale M; Guarino D; Martinetti A; Basso M; Mennitto R; Santonocito C; Mennitto A; Schinzari G; Bossi I; Capoluongo E; Danesi R; de Braud F; Barone C
Oncotarget; 2017 Mar; 8(10):16887-16898. PubMed ID: 28129643
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK; Antonacopoulou AG; Eleftheraki AG; Dimitrakopoulos FI; Koumarianou A; Varthalitis I; Fostira F; Sgouros J; Briasoulis E; Bournakis E; Bafaloukos D; Bompolaki I; Galani E; Kalogeras KT; Pectasides D; Fountzilas G; Kalofonos HP
Pharmacogenomics J; 2012 Dec; 12(6):468-75. PubMed ID: 21844885
[TBL] [Abstract][Full Text] [Related]
26. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
29. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
30. Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab.
Hansen TF; Andersen RF; Olsen DA; Sørensen FB; Jakobsen A
Sci Rep; 2017 May; 7(1):2388. PubMed ID: 28539619
[TBL] [Abstract][Full Text] [Related]
31. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
[TBL] [Abstract][Full Text] [Related]
34. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.
Zuurbier L; Rahman A; Cordes M; Scheick J; Wong TJ; Rustenburg F; Joseph JC; Dynoodt P; Casey R; Drillenburg P; Gerhards M; Barat A; Klinger R; Fender B; O'Connor DP; Betge J; Ebert MP; Gaiser T; Prehn JHM; Griffioen AW; van Grieken NCT; Ylstra B; Byrne AT; van der Flier LG; Gallagher WM; Postel R
Oncotarget; 2017 Jun; 8(26):42949-42961. PubMed ID: 28487489
[TBL] [Abstract][Full Text] [Related]
35. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.
Marisi G; Scarpi E; Passardi A; Nanni O; Ragazzini A; Valgiusti M; Casadei Gardini A; Neri LM; Frassineti GL; Amadori D; Ulivi P
Sci Rep; 2017 May; 7(1):1293. PubMed ID: 28465540
[TBL] [Abstract][Full Text] [Related]
36. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
37. Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
Marisi G; Azzali I; Passardi A; Rebuzzi F; Bartolini G; Urbini M; Canale M; Molinari C; Matteucci L; Sullo FG; Debonis SA; Gallio C; Gallo G; Frassineti GL; Ulivi P
Sci Rep; 2023 Aug; 13(1):12921. PubMed ID: 37558720
[TBL] [Abstract][Full Text] [Related]
38. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
Khan SA; Zeng Z; Shia J; Paty PB
Pathol Oncol Res; 2017 Jul; 23(3):673-677. PubMed ID: 28025786
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.
Giampieri R; Salvatore L; Del Prete M; Prochilo T; D'Anzeo M; Loretelli C; Loupakis F; Aprile G; Maccaroni E; Andrikou K; Bianconi M; Bittoni A; Faloppi L; Demurtas L; Montironi R; Scarpelli M; Falcone A; Zaniboni A; Scartozzi M; Cascinu S
Sci Rep; 2016 Apr; 6():25195. PubMed ID: 27117754
[TBL] [Abstract][Full Text] [Related]
40. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.
Houts AC; Ogale S; Zafar Y; Hubbard JM; Satram-Hoang S; Sommer N; Walker MS
J Gastrointest Cancer; 2019 Mar; 50(1):16-22. PubMed ID: 29058260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
